Compare abrdn Income Credit Strategies Fund (ACP) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Cassava Sciences Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.11 (market cap $637.39M), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: abrdn Income Credit Strategies Fund is far larger — about 13.3× Cassava Sciences Inc's market cap, and abrdn Income Credit Strategies Fund pays a 18.31% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| ACP | FLNA | |
|---|---|---|
Market Cap | $637.39M | $47.75M |
Sector | Financials | Health |
52-Week High | $5.98 | $4.64 |
52-Week Low | $5.01 | $0.87 |
Dividend Yield | 18.31% | — |
Enterprise Value | — | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.08, up 0.4% today, with a bearish technical signal from moving averages and a neutral stance from oscillators. The stock shows a low P/E of 7.7 and P/B of 0.9, indicating potential undervaluation, while net income margin remains high at 95.31%. Recent news highlights dividend declarations but also concerns over distribution sustainability from Seeking Alpha (2026-05-29).
The outlook is mixed: attractive valuation and dividends offer income appeal, but technical weakness and high distribution reliance pose risks. Investors should weigh the fund's high yield against credit spread tightness and leverage exposure noted in analyst reports.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
